Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 ReplyArthritis and Rheumatology.  73:548-549. 2021
2021 A randomized, phase 2 study evaluating the efficacy and safety of anakinra in the treatment of gout flares.Arthritis and Rheumatology2021
2021 American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3Arthritis and Rheumatology.  73:e1-e12. 2021
2021 SARS CoV-2 infection among patients using immunomodulatory therapiesAnnals of the Rheumatic Diseases.  80:269-271. 2021
2020 Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective studyArchives of Osteoporosis.  15. 2020
2020 Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyBiology of Blood and Marrow Transplantation.  26:1784-1802. 2020
2020 Erratum to “Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture” [Clin Therapeut 42 (6) (2020) 1099–1107] (Clinical Therapeutics (2020) 42(6) (1099–1107.e1), (S0149291820301995), (10.1016/j.clinthera.2020.04.012)) 2020
2020 American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2Arthritis and Rheumatology.  72:e1-e12. 2020
2020 Cardiovascular safety risks associated with gout treatmentsExpert Opinion on Drug Safety.  19:1143-1154. 2020
2020 Physical activity measured using wearable activity tracking devices associated with gout flares 2020
2020 American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1Arthritis and Rheumatology.  72:1241-1251. 2020
2020 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnnals of the Rheumatic Diseases.  79:S685-S699. 2020
2020 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture 2020
2020 Imminent Fracture Risk: A Call to Action for RheumatologistsArthritis Care and Research.  72:741-743. 2020
2020 Gout is associated with an increased risk for incident heart failure among older adults: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study 2020
2020 Comorbidities in gout and hyperuricemia: Causality or epiphenomena?Current Opinion in Rheumatology.  32:126-133. 2020
2020 Simulation-based power and sample size calculation for designing interrupted time series analyses of count outcomes in evaluation of health policy interventionsContemporary Clinical Trials Communications.  17. 2020
2020 Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study RegistryArthritis Care and Research2020
2020 Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort StudyHypertension.  75:246-256. 2020
2019 Pragmatic Clinical Trials in OsteoporosisCurrent Osteoporosis Reports.  17:521-526. 2019
2019 ReplyArthritis and Rheumatology.  71:1771-1772. 2019
2019 Reply.Arthritis and Rheumatology.  71:1771-1772. 2019
2019 Characteristics of older adults using patient web portals to view their DXA resultsBMC Medical Informatics and Decision Making.  19. 2019
2019 Long-Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five-Year Observational StudyArthritis Care and Research.  71:993-1003. 2019
2019 Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four–Month Randomized, Double-Blind, Double-Dummy TrialArthritis and Rheumatology.  71:1174-1184. 2019
2019 Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid ArthritisCurrent Rheumatology Reports.  21. 2019
2019 Comparison of an interactive voice response system and smartphone application in the identification of gout flares 2019
2019 Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal womenBONE.  123:191-195. 2019
2019 Changing rates in fracture trends are temporally associated with declining testing and treatment: reality or ecologic fallacy?Current Opinion in Rheumatology.  31:316-320. 2019
2019 Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized TrialAmerican Journal of Medicine.  132:354-361. 2019
2019 Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in GoutArthritis Care and Research.  71:427-434. 2019
2019 Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational StudiesCalcified Tissue International.  104:193-200. 2019
2019 Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.Core Evidence.  14:41-50. 2019
2019 Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled StudyArthritis and Rheumatology.  71:143-153. 2019
2019 Glucocorticoid-induced osteoporosis updateCurrent Opinion in Rheumatology.  31:388-393. 2019
2018 Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) studyArchives of Osteoporosis.  13. 2018
2018 Importance of Recent Fracture as Predictor of Imminent Fracture RiskCurrent Osteoporosis Reports.  16:738-745. 2018
2018 Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical TrialsArchives of Physical Medicine and Rehabilitation.  99:2637-2648. 2018
2018 The prevalence of overtreatment of osteoporosis: results from the PAADRN trialArchives of Osteoporosis.  13. 2018
2018 Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?Arthritis Care and Research.  70:1694-1699. 2018
2018 Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studiesBONE.  116:58-66. 2018
2018 Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitorsAnnals of the Rheumatic Diseases.  77:1012-1016. 2018
2018 A Performing Arts Intervention Improves Cognitive Dysfunction in 50 Hospitalized Older Adults.Innovation in Aging.  2:igy013. 2018
2018 Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: Phase II placebo-controlled study 2018
2018 Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based studyAnnals of the Rheumatic Diseases.  77:386-392. 2018
2018 Brief Report: Validation of a Definition of Flare in Patients With Established GoutArthritis and Rheumatology.  70:462-467. 2018
2018 Development and Pilot Testing of Multimedia Patient Education Tools for Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid ArthritisArthritis Care and Research.  70:213-220. 2018
2018 Just the FRAX: Management of Glucocorticoid-Induced OsteoporosisGastroenterology.  154:748-750. 2018
2018 Healthcare Providers' Recommendations for Physical Activity among US Arthritis Population: A Cross-Sectional Analysis by Race/Ethnicity.Arthritis.  2018:2807035. 2018
2017 Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled StudyArthritis and Rheumatology.  69:2386-2395. 2017
2017 Response to the American College of Physicians Osteoporosis Guideline, 2017 UpdateArthritis and Rheumatology.  69:2097-2101. 2017
2017 Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease OutcomesArthritis Care and Research.  69:1617-1619. 2017
2017 Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid ArthritisArthritis Care and Research.  69:1526-1534. 2017
2017 Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United StatesArthritis and Rheumatology.  69:1733-1740. 2017
2017 Management of goutAnnals of Internal Medicine.  166:855. 2017
2017 ReplyArthritis and Rheumatology.  69:1122. 2017
2017 Treat-To-Target (T2T) recommendations for goutAnnals of the Rheumatic Diseases.  76:632-638. 2017
2017 Sex differences in gout characteristics: Tailoring care for women and menBMC Musculoskeletal Disorders.  18. 2017
2017 Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysisAnnals of the Rheumatic Diseases.  76:543-546. 2017
2017 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnnals of the Rheumatic Diseases.  76:960-977. 2017
2017 Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study)Arthritis and Rheumatology.  69:203-212. 2017
2016 A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention materialContemporary Clinical Trials Communications.  4:14-24. 2016
2016 Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trialsContemporary Clinical Trials Communications.  4:136-140. 2016
2016 The National Osteoporosis Foundation’s methods and processes for developing position statementsArchives of Osteoporosis.  11. 2016
2016 Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac 2016
2016 Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1813-1818. 2016
2016 ReplyArthritis and Rheumatology.  68:2564. 2016
2016 Socio-demographic differences in risk information seeking sources for non-steroidal anti-inflammatory drugs (NSAIDS)International Journal of Medical Informatics.  94:222-227. 2016
2016 Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritisBMC Musculoskeletal Disorders.  17. 2016
2016 The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis 2016
2016 Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) StudyContemporary Clinical Trials.  50:106-115. 2016
2016 Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for VaccinationArthritis and Rheumatology.  68:2328-2337. 2016
2016 The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationaleContemporary Clinical Trials.  50:238-244. 2016
2016 Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy–Induced Osteoporosis Treated With Alendronate or TeriparatideArthritis and Rheumatology.  68:2122-2128. 2016
2016 Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: A randomized controlled trialBMC Musculoskeletal Disorders.  17. 2016
2016 A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis studyContemporary Clinical Trials Communications.  3:32-38. 2016
2016 Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal ImpairmentArthritis and Rheumatology.  68:2035-2043. 2016
2016 ReplyArthritis and Rheumatology.  68:1316-1318. 2016
2016 ReplyArthritis Care and Research.  68:725-726. 2016
2016 Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)Aging Clinical and Experimental Research.  28. 2016
2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
2016 Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in MedicareArthritis and Rheumatology.  68:56-66. 2016
2015 The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare populationBritish Journal of Clinical Pharmacology.  80:1447-1457. 2015
2015 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative InitiativeArthritis and Rheumatology.  67:2557-2568. 2015
2015 2015 Gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases.  74:1789-1798. 2015
2015 Bisphosphonates and glucocorticoid-induced osteoporosis: consEndocrine.  49:628-634. 2015
2015 Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatologyAnnals of the Rheumatic Diseases.  74:963-969. 2015
2015 Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapyAnnals of the Rheumatic Diseases.  74:1065-1071. 2015
2015 Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritisActa Reumatologica Portuguesa.  2015:10-22. 2015
2015 Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.Acta Reumatologica Portuguesa.  40:10-22. 2015
2015 Evaluating and mitigating fracture risk in established rheumatoid arthritisBest Practice and Research: Clinical Rheumatology.  29:614-627. 2015
2015 Fractures and mortality in relation to different osteoporosis treatmentsClinical and Experimental Rheumatology.  33:302-309. 2015
2015 Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patientsArthritis Care and Research.  67:624-632. 2015
2015 Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumabArthritis and Rheumatology.  67:1456-1464. 2015
2015 Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapyArthritis Care and Research.  67:731-736. 2015
2015 What is the relationship between morning symptoms and measures of disease activity in patients with rheumatoid arthritis?Arthritis Care and Research.  67:1202-1209. 2015
2014 Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) studyAnnals of the Rheumatic Diseases.  73:1942-1948. 2014
2014 Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United StatesArthritis Care and Research.  66:1604-1611. 2014
2014 Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: Meta-regression based on two systematic literature reviews 2014
2014 Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiariesBMC Musculoskeletal Disorders.  15. 2014
2014 Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global longitudinal study of osteoporosis in women (GLOW)Calcified Tissue International.  94:223-231. 2014
2014 Use of health plan combined with registry data to predict clinical trial recruitmentClinical Trials.  11:96-101. 2014
2014 Bone safety of low-dose glucocorticoids in rheumatic diseasesAnnals of the New York Academy of Sciences.  1318:55-64. 2014
2014 Improving bone mineral density reporting to patients with an illustration of personal fracture riskBMC Medical Informatics and Decision Making.  14. 2014
2014 Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritisArthritis Care and Research.  66:990-997. 2014
2013 Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids 2013
2013 Prevention and treatment of bone changes associated with exposure to glucocorticoidsCurrent Osteoporosis Reports.  11:341-347. 2013
2013 Tumor necrosis factor, tuberculosis, testing, and treatment: Teeing up the questionsArthritis Care and Research.  65:1719-1721. 2013
2013 Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.Arthritis Care and Research.  65:1719-1721. 2013
2013 Serum urate association with hypertension in young adults: Analysis from the Coronary Artery Risk Development in Young Adults cohortAnnals of the Rheumatic Diseases.  72:1321-1327. 2013
2013 Serum urate levels and consumption of common beverages and alcohol among chinese in SingaporeArthritis Care and Research.  65:1432-1440. 2013
2013 Study design considerations for a large simple trial of bisphosphonatesCurrent Opinion in Rheumatology.  25:517-523. 2013
2013 Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritisArthritis and Rheumatism.  65:1384-1389. 2013
2013 ReplyArthritis Care and Research.  65:832-833. 2013
2013 Gout-related health care utilization in US emergency departments, 2006 through 2008Arthritis Care and Research.  65:571-577. 2013
2013 Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2)Annals of the Rheumatic Diseases.  72:204-210. 2013
2013 Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting SystemArthritis Care and Research.  65:235-243. 2013
2013 Cardiovascular risk in rheumatoid arthritis: Comparing tnf-α blockade with nonbiologic DMARDsAmerican Journal of Medicine.  126:730.e9-730.e17. 2013
2013 Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should questionArthritis Care and Research.  65:329-339. 2013
2013 Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) studyAmerican Journal of Ophthalmology.  155:183-189.e1. 2013
2013 Osteopenia: Debates and dilemmasCurrent Rheumatology Reports.  15. 2013
2013 The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone healthContemporary Clinical Trials.  34:90-100. 2013
2013 Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare programArthritis Care and Research.  65:1743-1751. 2013
2013 Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesArthritis and Rheumatism.  65:48-58. 2013
2012 Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational dataArthritis Care and Research.  64:1855-1863. 2012
2012 Preliminary Competencies for Comparative Effectiveness ResearchClinical and Translational Science.  5:476-479. 2012
2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesContemporary Clinical Trials.  33:1211-1216. 2012
2012 Short-term and long-term safety of glucocorticoids in rheumatoid arthritisBulletin of the Hospital for Joint Diseases.  70. 2012
2012 ReplyArthritis Care and Research.  64:1623-1624. 2012
2012 Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy studyArthritis Care and Research.  64:1462-1470. 2012
2012 Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patientsArthritis Care and Research.  64:1480-1489. 2012
2012 Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentArthritis and Rheumatism.  64:2773-2780. 2012
2012 Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare populationArthritis Care and Research.  64:1054-1060. 2012
2012 Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)BONE.  50:1288-1293. 2012
2012 From fracture risk prediction to evaluating fracture patterns: Recent advances in the epidemiology of osteoporosisCurrent Rheumatology Reports.  14:205-211. 2012
2012 Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health StudyAnnals of the Rheumatic Diseases.  71:924-928. 2012
2012 Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practiceArthritis Care and Research.  64:640-647. 2012
2012 Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseasesArthritis Care and Research.  64:612-615. 2012
2012 Corrigendum to "Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate" [Bone 50 (2012) 289-295]BONE.  50:811. 2012
2012 Drug treatment of hyperuricemia to prevent cardiovascular outcomes: Are we there yet?American Journal of Cardiovascular Drugs.  12:1-6. 2012
2012 Association between being African-American, serum urate levels and the risk of developing hyperuricemia: Findings from the Coronary Artery Risk Development in Young Adults cohort 2012
2012 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care and Research.  64:625-639. 2012
2012 Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronateBONE.  50:289-295. 2012
2012 Developing a provisional definition of flare in patients with established goutArthritis and Rheumatism.  64:1508-1517. 2012
2012 Improving osteoporosis care in high-risk home health patients through a high-intensity interventionContemporary Clinical Trials.  33:206-212. 2012
2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
2012 ReplyArthritis Care and Research.  64:157-158. 2012
2011 The safety of low-dose glucocorticoids in rheumatic diseasesClinical and Experimental Rheumatology.  29. 2011
2011 Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis 2011
2011 Is two better than one? Combining antiresorptive and anabolic osteoporosis medicationsCurrent Osteoporosis Reports.  9:109-111. 2011
2011 Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)BONE.  49:493-498. 2011
2011 ReplyArthritis Care and Research.  63:1355. 2011
2011 The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsAnnals of the Rheumatic Diseases.  70:1401-1406. 2011
2011 Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapiesCurrent Rheumatology Reports.  13:273-282. 2011
2011 Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Arthritis and Rheumatism.  63:325-328. 2011
2011 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Arthritis Care and Research.  63:465-482. 2011
2011 Defining quality of care in rheumatology: The American College of rheumatology white paper on quality measurementArthritis Care and Research.  63:2-9. 2011
2011 Obesity is not protective against fracture in postmenopausal women: GlowAmerican Journal of Medicine.  124:1043-1050. 2011
2010 Serum urate and its relationship with alcoholic beverage intake in men and women: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohortAnnals of the Rheumatic Diseases.  69:1965-1970. 2010
2010 Medication assistance programs: Do all in need benefit equally?Ethnicity and Disease.  20:339-345. 2010
2010 From bone biology to clinical outcome: State of the art and future perspectivesAnnals of the Rheumatic Diseases.  69:1415-1419. 2010
2010 The delivery of evidence-based preventive care for older Americans with arthritis 2010
2010 Current Opinion in Rheumatology: Editorial introductionsCurrent Opinion in Rheumatology.  22. 2010
2010 Identifying types of nursing facility stays using medicare claims data: An algorithm and validation 2010
2010 Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases.  69:1015-1021. 2010
2010 ReplyArthritis and Rheumatism.  62:1837-1838. 2010
2010 Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronateBONE.  46:929-934. 2010
2010 The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awarenessAnnals of Pharmacotherapy.  44:274-284. 2010
2010 American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Care and Research.  62:1515-1526. 2010
2009 Febuxostat: The evidence for its use in the treatment of hyperuricemia and goutCore Evidence.  4:25-36. 2009
2009 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trialArthritis and Rheumatism.  60:3346-3355. 2009
2009 Progress in osteoporosis and fracture prevention: Focus on postmenopausal women 2009
2009 Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?Current Osteoporosis Reports.  7:27-34. 2009
2009 Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? 2009
2009 Editorial introductionsCurrent Opinion in Rheumatology.  21. 2009
2009 Toward a Valid Definition of Gout Flare: Results of Consensus Exercises Using Delphi Methodology and Cognitive MappingArthritis Care and Research.  61:535-543. 2009
2009 To the EditorsArthritis Care and Research.  61:285-286. 2009
2009 ReplyArthritis Care and Research.  61:142. 2009
2009 Glucocorticoids and the risk of osteoporosisExpert Opinion on Drug Safety.  8:33-47. 2009
2009 Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and EuropeAmerican Journal of Medicine.  122:S3. 2009
2009 Strategies for treating rheumatoid arthritis: New guidelines from the ACRInternational Journal of Clinical Rheumatology.  4:3-5. 2009
2008 Effect of racial differences on ability to afford prescription medicationsAmerican Journal of Health-System Pharmacy.  65:2137-2143. 2008
2008 Management of Hyperuricemia and Gout in CKDAmerican Journal of Kidney Diseases.  52:994-1009. 2008
2008 Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?Annals of the Rheumatic Diseases.  67:1358-1359. 2008
2008 Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26. 2008
2008 Mortality and osteoporotic fractures: is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26:S125-S137. 2008
2008 Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paperArthritis Care and Research.  59:1058-1073. 2008
2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Care and Research.  59:762-784. 2008
2008 Association of infections and tuberculosis with antitumor necrosis factor alpha therapyCurrent Opinion in Rheumatology.  20:320-326. 2008
2008 Biologics and heart failure in rheumatoid arthritis: Are we any wiser?Current Opinion in Rheumatology.  20:327-333. 2008
2008 Improving quality of care in osteoporosis: Opportunities and challengesCurrent Rheumatology Reports.  10:123-130. 2008
2008 The use of zoledronic acid for osteoporosis.Current Rheumatology Reports.  10:89-91. 2008
2008 Therapeutic advances in calcium and vitamin D for osteoporosis.Current Rheumatology Reports.  10:90-91. 2008
2008 The epidemiology of glucocorticoid-associated adverse eventsCurrent Opinion in Rheumatology.  20:131-137. 2008
2008 Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugsArthritis Care and Research.  59:227-233. 2008
2008 Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine. 2008
2007 Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behaviorArthritis Care and Research.  57:1539-1545. 2007
2007 Challenges in defining and improving osteoporosis quality of careClinical and Experimental Rheumatology.  25. 2007
2007 IntroductionClinical and Experimental Rheumatology.  25. 2007
2007 Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:4226-4227. 2007
2007 EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases.  66:1560-1567. 2007
2007 Challenges in defining and improving osteoporosis quality of care.Clinical and Experimental Rheumatology.  25:142-146. 2007
2007 Randomized Trial to Improve Fracture Prevention in Nursing Home ResidentsAmerican Journal of Medicine.  120:886-892. 2007
2007 Mend the mind, but mind the bones! Balancing benefits and potential skeletal risks of serotonin reuptake inhibitorsArchives of Internal Medicine.  167:1231-1232. 2007
2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBONE.  40:1238-1243. 2007
2007 Denosumab in postmenopausal women with low bone mineral density.Current Rheumatology Reports.  9:48. 2007
2007 Effect of reproductive factors on rheumatoid arthritisFuture Rheumatology.  2:177-183. 2007
2007 Ibandronate injections in postmenopausal women with osteoporosis.Current Rheumatology Reports.  9:47. 2007
2007 New directions in osteoporosis therapy: Intravenous ibandronate and denosumabCurrent Rheumatology Reports.  9:47-49. 2007
2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:1125-1133. 2007
2007 Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trialArchives of Internal Medicine.  167:591-596. 2007
2007 Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugsArthritis Care and Research.  57:343-346. 2007
2007 Prevention and treatment of glucocorticoid-induced osteoporosisCurrent Osteoporosis Reports.  5:14-21. 2007
2007 Validity of gout diagnoses in administrative dataArthritis Care and Research.  57:103-108. 2007
2006 Osteoporosis in the home health care setting: A window of opportunity?Arthritis Care and Research.  55:971-975. 2006
2006 Treatment of rheumatoid arthritisAmerican Journal of Health-System Pharmacy.  63:2451-2465. 2006
2006 Improving the quality of clinical care for patients with osteoporosis 2006
2006 IntroductionAmerican Journal of Medicine.  119. 2006
2006 Sex differences in gout epidemiology: Evaluation and treatmentAnnals of the Rheumatic Diseases.  65:1368-1372. 2006
2006 Pathophysiology, clinical presentation and treatment of goutDrugs.  66:1547-1563. 2006
2006 Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritisAnnals of the Rheumatic Diseases.  65:1213-1218. 2006
2006 Smoking interacts with genetic risk factors in the development of rheumatoid arthritis among older Caucasian womenAnnals of the Rheumatic Diseases.  65:1163-1167. 2006
2006 Osteoporotic fractures in older adultsBest Practice and Research: Clinical Rheumatology.  20:695-706. 2006
2006 Population-based assessment of adverse events associated with long-term glucocorticoid useArthritis Care and Research.  55:420-426. 2006
2006 Agreement between medical record documentation and patient-reported use of nonsteroidal antiinflammatory drugsAmerican Journal of Health-System Pharmacy.  63:744-747. 2006
2006 Epidemiology, risk factors, and lifestyle modifications for gout 2006
2006 New insights into gout epidemiologyCurrent Opinion in Rheumatology.  18:199-203. 2006
2006 Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial dataAnnals of the Rheumatic Diseases.  65:285-293. 2006
2006 Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophyAIDS Research and Human Retroviruses.  22:125-131. 2006
2006 Low-dose prednisolone in early rheumatoid arthritisCurrent Rheumatology Reports.  8:48-49. 2006
2006 The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: What can we learn about bone effects of glucocorticoids from randomized controlled trials?Current Rheumatology Reports.  8:47-48. 2006
2005 A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugsAmerican Journal of Managed Care.  11:537-543. 2005
2005 Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patientsArthritis and Rheumatism.  52:2485-2494. 2005
2005 Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999Annals of the Rheumatic Diseases.  64:267-272. 2005
2005 Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?Current Rheumatology Reports.  7:242-249. 2005
2005 Recent advances in the epidemiology of gout.Current Rheumatology Reports.  7:235-241. 2005
2004 Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risksClinical and Experimental Rheumatology.  22. 2004
2004 Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks.Clinical and Experimental Rheumatology.  22:S77-S82. 2004
2004 Evaluating and improving the quality of care in rheumatic disease 2004
2004 Measuring quality in arthritis care: The arthritis foundation's quality indicator set for analgesicsArthritis Care and Research.  51:337-349. 2004
2004 Measuring Quality in Arthritis Care: Methods for Developing the Arthritis Foundation's Quality Indicator SetArthritis Care and Research.  51:193-202. 2004
2004 Quality of Care Indicators for Gout ManagementArthritis and Rheumatism.  50:937-943. 2004
2004 Incidence of hip osteonecrosis among renal transplantation recipients: A prospective studyClinical Radiology.  59:431-438. 2004
2004 Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health StudyArthritis and Rheumatism.  50:72-77. 2004
2003 Glucocorticoids in the treatment of early and late RAAnnals of the Rheumatic Diseases.  62:1033-1037. 2003
2003 Osteoporosis: Evaluation and treatment 2003
2003 The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibsArthritis Care and Research.  49:293-299. 2003
2003 Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older womenAmerican Journal of Epidemiology.  157:345-354. 2003
2003 Glucocorticoid-induced osteoporosisEndocrinology and Metabolism Clinics of North America.  32:135-157. 2003
2002 Intolerance to caffeine may increase susceptibility to rheumatoid arthritis: Comment on the article by Mikuls et al [3] (multiple letters)Arthritis and Rheumatism.  46:3104. 2002
2002 Health-related quality of life in Gulf War era military personnelAmerican Journal of Epidemiology.  155:899-907. 2002
2002 Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: Results from the Iowa Women's Health StudyAmerican Journal of Medicine.  112:465-471. 2002
2002 Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa women's health studyArthritis and Rheumatism.  46:83-91. 2002
2002 Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study.Arthritis and Rheumatism.  46:83-91. 2002
2002 Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging studyArthritis and Rheumatism.  46:2020-2028. 2002
2002 Glucocorticoid therapy for arthritis: Overcoming the problemsDrug Benefit Trends.  14:39-43+52. 2002
2002 Glucocorticoid use in rheumatoid arthritis.Current Rheumatology Reports.  4:218-225. 2002
2002 Metabolic bone diseaseCurrent Opinion in Rheumatology.  14:404-405. 2002
2002 Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health StudyAnnals of the Rheumatic Diseases.  61:994-999. 2002
2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosisArthritis and Rheumatism.  44:1496-1503. 2001
2001 Resolved: Low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritisArthritis Care and Research.  45:468-471. 2001
2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trialArthritis and Rheumatism.  44:202-211. 2001
2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.Arthritis and Rheumatism.  44:202-211. 2001
2001 Use of complementary and alternative medicine by older patients with arthritis: A population-based studyArthritis Care and Research.  45:398-403. 2001
2000 Erratum: Rofecoxib: A viewpoint by R.H. Hunt. Guest commentary (Drugs (1999) 58 (3) (506-507))Drugs.  59:179. 2000
2000 Moderate-term, low-dose corticosteroids for rheumatoid arthritis.Cochrane Database of Systematic Reviews2000
2000 Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritisArchives of Family Medicine.  9:1124-1134. 2000
1999 Rofecoxib. ViewpointsDrugs.  58:506. 1999
1998 Nonsteroidal anti-inflammatory drugs and cognitive function. Do they have a beneficial or deleterious effect?Drug Safety.  19:427-433. 1998
1998 Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factorsArthritis and Rheumatism.  11:177-185. 1998
1998 Arthritis health service utilization among the elderly: The role of urban-rural residence and other utilization factorsArthritis and Rheumatism.  11:177-185. 1998
1997 Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidenceAmerican Journal of Medicine.  103. 1997
1997 Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence.American Journal of Medicine.  103:31S-39S. 1997
1997 Health services researchCurrent Opinion in Rheumatology.  9:118-125. 1997
1997 Mixed connective tissue disease and radiation toxicity: A case reportCancer.  79:612-618. 1997
1997 Cigarette smoking and rheumatoid arthritis severityAnnals of the Rheumatic Diseases.  56:463-469. 1997
1996 Low-dose corticosteroids in rheumatoid arthritis: A meta-analysis of their moderate-term effectivenessArthritis and Rheumatism.  39:1818-1825. 1996
1996 Methotrexate patient education: A quality improvement studyArthritis and Rheumatism.  9:216-222. 1996
1996 Methotrexate patient education: A quality improvement studyArthritis and Rheumatism.  9:216-222. 1996
1996 Rheumatoid arthritis lung disease: Determinants of radiographic and physiologic abnormalitiesArthritis and Rheumatism.  39:1711-1719. 1996
1996 The foot function index for measuring rheumatoid arthritis pain: Evaluating side-to-side reliabilityFoot and Ankle International.  17:506-510. 1996
1995 Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritisAmerican Journal of Medicine.  99:692-693. 1995
1995 The replyAmerican Journal of Medicine.  99:693-694. 1995
1994 Low dose long-term corticosteroid therapy in rheumatoid arthritis : an analysis of serious adverse eventsAm J Med.  96:115-123. 1994
1994 Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsAmerican Journal of Medicine.  96:115-123. 1994
1989 Infectious Diarrhea Secondary to Enteromonas hominisAmerican Journal of Gastroenterology.  84:1313-1314. 1989

Book

Year Title Altmetric
2009 Preface.  Ed. 23.  2009

Chapter

Year Title Altmetric
2018 Glucocorticoid-induced osteoporosis.  467-473. 2018
2015 Systemic glucocorticoids in rheumatology.  423-433. 2015
2013 Epidemiology of gout.  7-23. 2013
2013 Glucocorticoid-Induced Osteoporosis.  1191-1223. 2013
2009 Osteoporosis.  393-404. 2009
2008 Glucocorticoid-Induced Osteoporosis.  1135-1166. 2008
2008 Osteoporosis A. epidemiology and clinical assessment.  576-583. 2008
2005 Prevention and Treatment 2005
2001 Glucocorticoid-induced osteoporosis.  140-145. 2001

Principal Investigator On

  • Private Grant  awarded by HORIZON THERAPEUTICS 2021 - 2026
  • Private Grant  awarded by HORIZON THERAPEUTICS 2021 - 2026
  • Private Grant  awarded by LG CHEM LTD 2020 - 2025
  • Private Grant  awarded by DYVE BIOSCIENCES, INC 2020 - 2025
  • Deep South Translational Research Mentored Career Development Program (CCTS)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • NRSA Training Core (CCTS)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • Private Grant  awarded by AMGEN, INC.^ 2020 - 2024
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2019 - 2022
  • Private Grant  awarded by HORIZON PHARMA RHEUMATOLOGY LLC 2019 - 2022
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2017 - 2022
  • Private Grant  awarded by RADIUS HEALTH 2019 - 2022
  • CF Admin Core (Old) to New  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • CF Project 2 (Old) to New  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • CF Project 3 (OLD) to new  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • CF Project 4 (OLD) to new  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Improving Minority Gout Care and Clinical Research Participation in the Southeast  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 1: AMPK and Inflammation in Gout  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 2: Novel Risk Factors and Precision Medicine for Gout Flares  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 3: Translational Genomics of Hyperuricemia  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by AMPEL BIOSOLUTIONS 2016 - 2021
  • Strengthening Translational Research in Diverse Enrollment (STRIDE)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER) 2016 - 2021
  • Private Grant  awarded by MEREO BIOPHARMA 3 LIMITED 2017 - 2021
  • Private Grant  awarded by KIBOW BIOTECH 2019 - 2020
  • Private Grant  awarded by RADIUS HEALTH 2018 - 2020
  • Private Grant  awarded by SHANTON PHARMA CO. LTD 2019 - 2020
  • T32 In Health Services Research Training Program  awarded by Agency for Healthcare Research and Quality/DHHS 2018 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Promo/Dissemination Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by ACTIVE LIFE SCIENTIFIC, INC. 2018 - 2020
  • REduCing Immunogenicity to PegloticasE (RECIPE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2018 - 2020
  • Private Grant  awarded by AMGEN, INC.^ 2018 - 2020
  • UAB Center for Clinical and Translational Science (CCTS) (TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (KL2)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB K12 in Patient Centered Outcomes Research  awarded by Agency for Healthcare Research and Quality/DHHS 2014 - 2019
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB 2017 - 2019
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2019
  • UAB Health Services, Outcomes, and Effectiveness Research Training Program  awarded by Agency for Healthcare Research and Quality/DHHS 2013 - 2018
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2018
  • Private Grant  awarded by AMGEN, INC.^ 2012 - 2018
  • Private Grant  awarded by AMGEN, INC.^ 2012 - 2018
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Project 2  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Centers of Research Translation (CoRT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • UAB Deep South Arthritis and Musculoskeletal CERTs  awarded by Agency for Healthcare Research and Quality/DHHS 2011 - 2017
  • Activating Patients to Reduce Osteoporosis (APROPOS)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2011 - 2017
  • Patient-Centered Outcomes Research Translation Center  awarded by Baylor University 2016 - 2017
  • Private Grant  awarded by SAVIENT PHARMACEUTICALS 2012 - 2017
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2013 - 2017
  • Private Grant  awarded by ELI LILLY AND COMPANY 2014 - 2016
  • Private Grant  awarded by HORIZON PHARMA USA, INC. 2016
  • Pilot Studies for the Active Comparator Osteoporosis Large Simple Trial (ATLAST)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2016
  • Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2016
  • A Patient Activation Intervention to Improve Bone Health in Older Adults  awarded by University of Iowa 2010 - 2016
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2015 - 2016
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2014 - 2016
  • Private Grant  awarded by CREALTA PHARMACEUTICALS, LLC - NEW 2015 - 2016
  • Mid-Career Investigator Award  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2010 - 2015
  • Patient Centered Outcomes Research Institutional Award (K12)  awarded by Agency for Healthcare Research and Quality/DHHS 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2013 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2012 - 2013
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2013
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2009 - 2013
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2011 - 2013
  • UAB K12 in Comparative Effectiveness Research  awarded by Agency for Healthcare Research and Quality/DHHS 2010 - 2013
  • UAB T32 in Comparative Effectiveness Research  awarded by Agency for Healthcare Research and Quality/DHHS 2010 - 2013
  • UAB Health Services & Outcomes Research Training Program  awarded by Agency for Healthcare Research and Quality/DHHS 2009 - 2013
  • Detection and Analysis of Adverse Events Related to Regulated Products in Automated Healthcare Data. Efforts to Develop the Sentinel Initiative  awarded by HARVARD PILGRIM HEALTH CARE 2011 - 2012
  • The Global Longitudinal Registry of Osteoporosis in Women (GLOW)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER) 2006 - 2012
  • Deep South Musculoskeletal Certs (DSMC)  awarded by Agency for Healthcare Research and Quality/DHHS 2007 - 2012
  • Private Grant  awarded by Procter & Gamble Company 2008 - 2012
  • Private Grant  awarded by AMGEN, INC.^ 2009 - 2012
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2009 - 2011
  • Private Grant  awarded by Sanofi US Services Inc 2009 - 2011
  • Private Grant  awarded by TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER 2010 - 2011
  • Improving Bone Health Among RA Patients on Chronic Glucocorticoids  awarded by American College of Rheumatology 2008 - 2011
  • Private Grant  awarded by ELI LILLY AND COMPANY 2004 - 2011
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2010 - 2011
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2009 - 2011
  • Private Grant  awarded by AMGEN, INC.^ 2010
  • Investigator On

  • Building and InnovatinG: Digital heALTH Technology and Analytics (BIGDATA)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2020 - 2024
  • Building and InnovatinG: Digital heAlth Technology and Analytics (BIGDATA) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2020 - 2024
  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • Modifications to Implement Lupus Decision-Aid Successfully in COVID-19 Era  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2021 - 2022
  • Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2020 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Project 4: Protecting Renal Function with Urate-Lowering Drugs  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • UAB Research and Education Program in Neuroscience  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • Implementation of DEcision-Aid for Lupus in Practice Settings for Shared Decision-Making (SOM): IDEAL Study  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2018 - 2021
  • Biology or Management: Understanding Racial Differences in Post Fracture Outcomes  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2021
  • DNA Sequencing for Newborn Nurseries in the South  awarded by HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY 2017 - 2021
  • Training Program in Rheumatic and Musculoskeletal Diseases Research  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2020 - 2021
  • Private Grant  awarded by AMGEN, INC.^ 2016 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Admin Oversight Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Coordinating Center  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Rehabilitation Research Resource to Enhance Clinical Trials (REACT)  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Training Program in Rheumatic and Musculoskeletal Diseases Research  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2016 - 2020
  • Skeletal Health in Bariatric Surgery Patients  awarded by American Society for Metabolic and Bariatric Surgery Foundation 2017 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • UAB Multidisciplinary Clinical Research Center - Core A (Administrative Core)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease to Improve Cardiovascular Outcomes  awarded by American Heart Association 2017 - 2018
  • Individualized Patient Decision Making for Treatment Choices Among Minorities with Lupus  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2013 - 2018
  • Private Grant  awarded by O.N. DIAGNOSTICS, LLC 2015 - 2017
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by Janssen 2016 - 2017
  • PROs in Inflammatory Arthritis: Electronic Capture to Improve Patient Outcomes  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2014 - 2017
  • A Pilot Study of the Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2013 - 2016
  • Private Grant  awarded by ABBVIE INC 2016
  • Arthritis Patient Partnership With Comparative Effectiveness Researchers (AR-Power PPRN)  awarded by GLOBAL HEALTHY LIVING FOUNDATION 2014 - 2015
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2014 - 2015
  • Longitudinal Comparative Effectiveness & Safety of Biologics in Autoimmunity  awarded by Agency for Healthcare Research and Quality/DHHS 2009 - 2014
  • Burden of Osteoporosis and Low Bone Density in the United States  awarded by National Osteoporosis Foundation 2012 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) KL2 Component  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • Using CERs to Optimize Quality of Life for Persons with Diabetes and Chronic Pain  awarded by Agency for Healthcare Research and Quality/DHHS 2010 - 2013
  • Comprehensive Minority and Health Disparities Research Center - ARRA Supplement  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS 2010 - 2012
  • Comprehensive Minority and Health Disparities Research Center  awarded by NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES/NIH/DHHS 2007 - 2012
  • Ethnic Differences in the Risk of Fracture and Vascular Disease  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2007 - 2012
  • Private Grant  awarded by AMGEN, INC.^ 2010 - 2012
  • Education And Training

  • Master of Science in Epidemiology, University of Iowa 1993
  • Doctor of Medicine, Northwestern University 1986
  • Northwestern Memorial Hospital, Residency 1990
  • University of Iowa Hospitals and Clinics, Postdoctoral Fellowship 1993
  • Full Name

  • Kenneth Saag